This is in reference to the complaints attached regarding the non-issuance of original health records to patients attending the Health Curative Department dispensaries. ..
New name reflects the Company’s strategic evolution focused on later-stage preclinical assets leveraging its most advanced, signature ...
Minaris and Genetix Biotherapeutics have expanded their manufacturing partnership to increase commercial-scale production of ...
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) and multimodality ...
The first GMP cell therapy product ever manufactured for clinical use on the Cell Shuttle™ and released using Cell Q™, is expected to be infused into patients within Cabaletta’s RESET™ clinical trial ...
The breakthrough tackles a longstanding challenge in genetic medicine with the goal of developing a new generation of ...
Tenaya plans to pursue regulatory alignment on TN-201 pivotal studies over the course of 2026 with an update to be released in the second half of the year. TN-201 was generally well tolerated at both ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a ...
Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback